Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.